CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. is trading at $3.61, up 7.29% on the session. The 50 day average sits at $3.44 and the 200 day at $4.16, which puts the stock in a downtrend. RSI is at 42.9, which reads as weak, and MACD is bearish crossover. Volume is below average.

The nearest support is around $3.18 with resistance near $3.55, so that band frames the current range. Average daily movement is roughly $0.17, or about 4.8% of the share price, which is what any stop placement has to allow for. The overall health score of 25 out of 100 combines a trend score of 3, momentum of 30 and a risk score of 52.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.